Skip to main content
. Author manuscript; available in PMC: 2018 Jul 30.
Published in final edited form as: N Engl J Med. 2018 Jun 26;379(2):150–161. doi: 10.1056/NEJMoa1716435

Figure 3. Axial T1-Weighted MRI, Obtained with the Use of Contrast Material, of the Eighth Patient Treated in the Study, at Dose Level 5.

Figure 3

Panel A shows the baseline MRI of this patient, who received dose level 5 (1010 TCID50). Panel B shows the image obtained after surgery for evacuation of intracranial hemorrhage after the removal of the infusion catheter. Panel C shows the image obtained at the time of disease progression, 7 months after the PVSRIPO infusion. Panel D shows the image obtained after the first cycle of lomustine, and Panel E the image obtained at the completion of nine cycles of lomustine. Panel F shows the results 1 year after the discontinuation of lomustine and 32 months after the PVSRIPO infusion.